Adamas Announces Pricing of Public Offering of Common Stock
January 06 2016 - 10:08PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the
pricing of its underwritten public offering of 2,500,000 shares of
its common stock at a price to the public of $23.00 per share.
Adamas also granted the underwriters a 30-day option to acquire an
additional 375,000 shares from Adamas. The offering is expected to
close on January 12, 2016, subject to customary closing conditions.
Cowen and Company, LLC and Piper Jaffray & Co. are acting as
book-running managers for the proposed offering, with William Blair
& Company, L.L.C., JMP Securities LLC and Trout Capital LLC
acting as co-managers.
A shelf registration statement relating to the shares was filed
with the Securities and Exchange Commission on May 18, 2015 and
became effective on June 1, 2015. The offering will be made only by
means of a prospectus supplement. When available, copies of the
prospectus supplement and accompanying prospectus relating to the
public offering may be obtained by contacting Cowen and Company,
LLC, c/o Broadridge Financial Services, Attention: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone:
631-274-2806, Fax: 631-254-7140; or Piper Jaffray & Co., 800
Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone:
800-747-3924, Email: prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is a biopharmaceutical company
committed to developing product candidates for the treatment of
chronic disorders of the central nervous system.
Forward-Looking Statements
This announcement contains forward-looking statements, including
statements relating to Adamas’ expectations regarding the
completion of the proposed public offering. These statements are
subject to significant risks and uncertainties, actual results
could differ materially from those projected and Adamas cautions
investors not to place undue reliance on the forward-looking
statements contained in this release. These risks and uncertainties
include, without limitation, risks and uncertainties related to
market conditions and satisfaction of customary closing conditions
related to the public offering. There can be no assurance that
Adamas will be able to complete the public offering on the
anticipated terms, or at all. Risks and uncertainties relating to
Adamas and its business can be found in the “Risk Factors” section
of Adamas’ Form 10-Q, filed with the SEC on November 12, 2015, and
in the preliminary prospectus supplement related to the proposed
offering filed with the SEC on January 5, 2016. Adamas undertakes
no duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future
events or changes in Adamas’ expectations.
For questions, please contact:
Julie Wood
Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
Phone: 510-450-3528
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Sep 2023 to Sep 2024